Background {#Sec1}
==========

Esophageal cancer is a common cause for cancer mortality around the world \[[@CR1]\], and except in North America and Europe, squamous cell carcinoma (SqCC) is the major histological subtype \[[@CR1]\].

The optimal treatment for locally advanced esophageal SqCC has remained elusive. According to the current National Comprehensive Cancer Network guidelines, esophagectomy, neoadjuvant concurrent chemoradiotherapy (CCRT) followed by esophagectomy, or definite CCRT were all possible treatment options for cT1b-4aN0-+M0 patients \[[@CR2]\]. A seminal paper published in the New England Journal of Medicine in 2014 states that "locally advanced tumors, defined as category T3N1, are best treated with esophagectomy" \[[@CR1]\]. However, the role of esophagectomy was questioned in a review paper published in 2017 \[[@CR3]\]. Meta-analyses and a recent large-scale randomized controlled trial (RCT) reported favorable outcomes when neoadjuvant CCRT followed by esophagectomy was compared to esophagectomy alone \[[@CR4], [@CR5]\]. In addition, RCTs for esophageal SqCC patients from Germany and France had reported similar overall survival (OS), although better local control was obtained with neoadjuvant CCRT followed by esophagectomy compared to CCRT without surgery (also mentioned in the 2017 review paper above) \[[@CR3], [@CR6], [@CR7]\]. Another RCT also reported similar OS between CCRT without surgery and upfront esophagectomy without neoadjuvant CCRT \[[@CR8]\].

Therefore, the aim of our study was to compare neoadjuvant CCRT followed by esophagectomy to definitive CCRT for locally advanced esophageal SqCC patients in a real-world Asian population.

Methods {#Sec2}
=======

Data source {#Sec3}
-----------

In our study, the primary data comes from the Taiwan Cancer Registry (TCR) and death registration. The TCR is a high-quality database \[[@CR9]\] that provides complete information such as individual demographics, stage of disease, tumor histology, and treatment details. Some prognostic factors, e.g., the use of positron emission tomography (PET), were also available since 2011.

Study population and study design {#Sec4}
---------------------------------

Our study flow chart, designed to conform to the STROBE guidelines \[[@CR10]\], is depicted in Fig. [1](#Fig1){ref-type="fig"}. The main study population consisted of locally advanced esophageal SqCC patients diagnosed from 2008 to 2015 who received neoadjuvant CCRT \[radiotherapy dose 40--50.4 Gy\] before esophagectomy, or CCRT \[radiotherapy dose ≥ 50.4 Gy\] without surgery. The explanatory variable of interest in this study was the surgery group (neoadjuvant CCRT followed by esophagectomy) vs the CCRT group (CCRT without surgery). We collected covariables based on our experiences in clinical care and related TCR studies \[[@CR11]--[@CR13]\] for adjustment of potential nonrandomized treatment selection (as mentioned in the next section). We defined the date of diagnosis from the cancer registry as the index date and obtained the survival statuses of patients from the death registry \[follow-up until Dec 31, 2016\]. We then estimated propensity scores (PSs) using the covariables to construct a PS-matched sample. We used this PS-based method rather than a Cox regression model, as suggested in previous literature \[[@CR14], [@CR15]\].Fig. 1STROBE study flow chart and the numbers of individuals at each stage of the study. 1: We only included those treated (classes 1--2) by any single institution to ensure data consistency. 2: Cancer staging clinical stage T3N1M0. 3: Without missing information in the TCR and the death registry

Other explanatory covariables {#Sec5}
-----------------------------

Patient demographics \[age, gender, residency region\], disease characteristics \[tumor size, differentiation, tumor location\], radiotherapy (RT) delivery, institution, and period were included in our primary analysis. We also considered a prognostic factor \["use of PET", available in the TCR since 2011\] in the supplementary analyses. The definitions of covariables were as follows. Patient residency region was classified as northern Taiwan or elsewhere. Tumor size was classified by a diameter ≤ 5 or \> 5 cm. Tumor differentiation was classified as well/moderately differentiated or poorly/undifferentiated. External beam radiotherapy delivery was classified as image-guided radiotherapy (IGRT) or non-IGRT. The hospital was classified as a high- or low-volume institute via a threshold \[20 esophagectomies per year\] \[[@CR16]\]. The time period was classified as 2008--2009 or 2010--2015. Tumor location was classified as cervical or not.

Statistical analysis {#Sec6}
--------------------

We performed the statistical analysis using the software SAS 9.4 (SAS Institute, Cary, NC, USA) and STATA 12 (StataCorp LP, College Station, TX, USA). In the primary analysis, we used a logistic regression model based on covariables to evaluate the probability of receiving surgery (vs CCRT) and then used the logit of the probability as the PS in a PS-matched method. Tabulation and standardized difference \[[@CR17], [@CR18]\] were used to assess the balance of covariates between PS-matched groups. We used a robust variance estimator to compare the hazard ratios of events between surgery- and CCRT-matched groups during the entire follow-up period \[[@CR14]\]. As suggested in the recent literature \[[@CR19]\], we evaluated the robustness of our findings to potential unmeasured confounding factor(s) via the E-factor. We also evaluated the outcomes of patients for freedom from local regional recurrence (FFLRR) and esophageal cancer-specific survival (ECSS) according to the TCR and the death registry.

Supplementary analysis {#Sec7}
----------------------

In a subgroup of patients \[diagnosed from 2011 to 2015\] for whom additional information, i.e., use of PET, was available, we performed the first supplementary analysis (SA-1). In the second supplementary analysis (SA-2), we repeated what we did in SA-1 but limited the surgery group to those who received minimally invasive esophagectomy (MIE) because of its potential superiority \[[@CR20], [@CR21]\]. In the third supplementary analysis (SA-3), we reanalyzed the OS in the primary analysis when the index date was changed to the start of radiotherapy.

Results {#Sec8}
=======

Identification of the study population used in the primary analysis {#Sec9}
-------------------------------------------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, the identified initial study population consisted of 451 esophageal SqCC cancer patients divided into surgery or CCRT groups. After excluding the missing data in follow-up and applying a PS matching method, 298 patients were used as the final study population in the primary analysis. The patient characteristics are described in Table [1](#Tab1){ref-type="table"}. All covariables after matching were well balanced with small standardized differences (\< 0.25) \[[@CR17]\].Table 1Characteristics of matched study population in the primary analysisSurgeryCCRTStandardized difference^a^Number or mean (sd)^a^(%)^a^Number or mean (sd)^a^(%)^a^Age56.93 (8.65)57.26 (10.48)0.04GenderFemale8(5)7(5)0.03Male141(95)142(95)ResidencyNon-north101(68)100(67)0.01North48(32)49(33)Tumor size≤ 5 cm59(40)60(40)0.01\> 5 cm90(60)89(60)DifferentiationPoorly/undifferentiated46(31)53(36)0.10Well/moderately103(69)96(64)RT deliveryNon-IGRT131(88)128(86)0.06IGRT18(12)21(14)InstitutionLow volume50(34)54(36)0.06High volume99(66)95(64)Period2008--200918(12)19(13)0.022010--2015131(88)130(87)LocationCervical1(1)1(1)0.00Noncervical148(99)148(99)*sd* standard deviation, *RT* radiotherapy, *IGRT* image-guided RT, *CCRT* concurrent chemoradiotherapy^a^Rounded

Primary analysis {#Sec10}
----------------

After a median follow-up of 20 months \[range 3--98\], death was observed for 79 patients in the surgery group and for 108 in the CCRT group. The hazard ratio (HR) of death when surgery was compared to CCRT was 0.56 \[95% confidence interval (95CI) 0.42--0.75, *p* value \< 0.001\]. The observed HR 0.56 for OS could be explained by an unmeasured confounder associated with the selection of treatment (IMRT or 3DCRT) and live/death by a risk ratio of 2.35-fold each; however, weaker confounding factors could not do so. Furthermore, the confidence interval could be moved to include the null hypothesis by an unmeasured confounder by a risk ratio of 1.74, above and beyond the measured confounders; however, weaker confounding could not. The 5-year OS rate for surgery was 38% (vs 20% for CCRT). Figure [2](#Fig2){ref-type="fig"} shows the Kaplan-Meier survival curve for OS. Surgery was also associated with better FFLRR \[HR 0.17, 95CI 0.11--0.28, *p* value \< .001\] and ECSS \[HR 0.56, 95CI 0.41--0.77, *p* value \< .001\].Fig. 2Kaplan-Meier survival curve (in years) for the final study population \[primary analysis\]

Supplementary analyses {#Sec11}
----------------------

In the SA-1, which incorporated the use of PET into the PS model, all of the covariables were well balanced and the standardized differences were small (\< 0.25) (Table [2](#Tab2){ref-type="table"}). From this analysis, we found that surgery was still associated with improved OS compared to CCRT \[HR 0.51, 95CI 0.36--0.72, *p* value \< 0.001\]. Figure [3](#Fig3){ref-type="fig"} shows the Kaplan-Meier survival curve for OS.Table 2Characteristics of the matched study population in the SA-1SurgeryCCRTStandardized difference^a^Number or mean (sd)^a^(%)^a^Number or mean (sd)^a^(%)^a^Age57.00 (7.63)56.61 (9.62)0.05GenderFemale6(5)3(3)0.14Male104(95)107(97)ResidencyNon-north76(69)80(73)0.08North34(31)30(27)Tumor size≤ 5 cm43(39)42(38)0.02\> 5 cm67(61)68(62)DifferentiationPoorly/undifferentiated41(37)42(38)0.02Well/moderately69(63)68(62)RT deliveryNon-IGRT94(85)96(87)0.05IGRT16(15)14(13)InstitutionLow volume40(36)45(41)0.09High volume70(64)65(59)Use of PETWithout12(11)12(11)0.00With98(89)98(89)LocationCervical1(1)1(1)0.00Noncervical109(99)109(99)*sd* standard deviation, *RT* radiotherapy, *IGRT* image-guided RT, *PET* positron emission tomography, *CCRT* concurrent chemoradiotherapy^a^RoundedFig. 3Kaplan-Meier survival curve (in years) for a PS-matched subgroup diagnosed from 2011 to 2015 \[SA-1\]

In the SA-2, in which neoadjuvant CCRT followed by MIE was compared to CCRT without surgery, all of the covariables were still well balanced with small standardized differences (\< 0.25) (Table [3](#Tab3){ref-type="table"}). The HR of death when surgery \[MIE\] was compared to CCRT was 0.44 \[95CI 0.28--0.70, *p* value \< 0.001\]. Figure [4](#Fig4){ref-type="fig"} shows the Kaplan-Meier survival curve for OS.Table 3Characteristics of the matched study population in the SA-2Surgery \[MIE\]CCRTStandardized difference^a^Number or mean (sd)^a^(%)^a^Number or mean (sd)^a^(%)^a^Age56.38 (8.21)55.35 (10.58)0.11GenderFemale4(5)4(5)0.00Male78(95)78(95)ResidencyNon-north57(70)52(63)0.13North25(30)30(37)Tumor size≤ 5 cm31(38)31(38)0.00\> 5 cm51(62)51(62)DifferentiationPoorly/undifferentiated31(38)30(37)0.03Well/moderately51(62)52(63)RT deliveryNon-IGRT70(85)68(83)0.07IGRT12(15)14(17)InstitutionLow volume23(28)25(30)0.05High volume59(72)57(70)Use of PETWithout7(9)11(13)0.16With75(91)71(87)The nonoverlapped covariable (location) was not included in this matching*sd* standard deviation, *RT* radiotherapy, *IGRT* image-guided RT, *PET* positron emission tomography, *MIE* minimally invasive esophagectomy, *CCRT* concurrent chemoradiotherapy^a^RoundedFig. 4Kaplan-Meier survival curve (in years) for a PS-matched subgroup diagnosed from 2011 to 2015, but with the surgery group limited to those who received MIE \[SA-2\]

In the SA-3 in which we used the RT-start date as the index date, the HR for death when surgery was compared with CCRT was similar \[0.55, 95CI 0.41--0.74, *p* value \< 0.001\]. The Kaplan-Meier survival curves for OS are shown in Fig. [5](#Fig5){ref-type="fig"}.Fig. 5Kaplan-Meier survival curve (in years) for the final study population when the index date was changed to the start of radiotherapy \[SA-3\]

Discussion {#Sec12}
==========

In this population-based study PS-matched analysis from Asia (Taiwan), we found that for locally advanced esophageal SqCC, neoadjuvant CCRT followed by esophagectomy was associated with improved OS when compared to CCRT without surgery.

Statistically, our results were not consistent with available RCTs \[[@CR6], [@CR7]\]; however, survival was actually numerically better for the surgical arm when compared to that for the nonsurgical arms in both RCTs, although not statistically significant. The 2-year OS was 39.9 vs 35.4% in the German trial \[[@CR7]\] and 37.1 vs 36.5% \[per protocol\] in the French trial \[[@CR6]\]. In our study, it was 63 vs 39%. Therefore, the outcome of CCRT in our study was similar to both RCTs, but the outcome of neoadjuvant CCRT followed by esophagectomy was higher in our study \[63%\] (although close to the 67% OS reported in the modern CROSS study \[[@CR5]\]).

We feel that our findings are compatible with the prevalent concept that esophagectomy is an integral part of treatment for locally advanced esophageal cancer \[[@CR1]\], possibly through improved disease control (demonstrated by the improved FFLRR and ECSS), as better local/regional control in the surgical arm had also been reported in the above RCTs \[[@CR6], [@CR7]\]. However, given the abovementioned RCTs and that our result was sensitive to potential unmeasured confounders \[E-factor 1.74\], we feel that our results should not be interpreted as conclusive and that further modern RCTs are needed. When we searched in "[https://clinicaltrials.gov/"](https://clinicaltrials.gov/) using \["esophagectomy" AND "concurrent chemoradiotherapy"\] on May 21, 2018, we found two relevant ongoing trials \[NCT02972372, NCT01740375\]; however, these trials were relevant but not identical. NCT02972372 investigated definitive CCRT vs surgery without neoadjuvant CCRT, whereas NCT01740375 investigated upfront surgery or observation for those patients who achieved complete clinical response. Therefore, the results of our study could be valuable for contemporary patient decision-making until other modern high-level evidence becomes available.

There were some limitations in our study. First, we shared the inherent limitation of observation study. Although we tried our best to follow the STROBE guidelines for observational study \[[@CR10]\] and examined extensive supplementary analyses, potential unmeasured confounder(s), such as presenting body weight loss \[[@CR6]\] or operability, might still threaten our results. Second, the generalizability of our finding to regions where SqCC was not the predominant histology might be questionable.

Conclusions {#Sec13}
===========

We found that for locally advanced esophageal SqCC, neoadjuvant CCRT followed by esophagectomy was associated with improved OS when compared to CCRT without surgery. However, given the nonrandomized nature of the study and sensitivity to potential unmeasured confounder(s), our results should be interpreted cautiously.
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